CBD intimate oil - 1200MG

Translation of the scientific study: " Molecular and biochemical mechanism of cannabldiol in the management of inflammatory and oxidative processes associated with endometriosis

Okten SB, Cetin C, Tok OE, Guler EM, Taha SH, Ozcan P, Ficicioglu C.

Reprod Biomed Online. 2023 May;46(5):865-875. doi: 10.1016/j.rbmo.2023.01.018. Epub 2023 Feb 2.

PMID: 36997400"

Endometriosis is usually associated with inflammation and chronic pelvic pain.

This article focuses on the anti-inflammatory, antioxidant and analgesic effects of cannabldiol (C8D) and its potential role in endometriosis.

Administration of C8D markedly reduced the diameter, volume and surface area of ​​the lesions.

In particular, C8D was able to modify the morphology of the lesions, reducing epithelial glands and stroma. C8D showed anti-oxidant effects reducing lipid peroxidation, expression of Nox-1 and Nox-4 enzymes. C8D restored the oxidative balance of endogenous cellular defense, as shown by SOD activity and GSH levels in lesions. C8D also showed significant antifibrotic effects, as shown by Masson's trichrome staining and reduced expression of MMP-9, iNOS, and TGF-β. C8D was able to reduce inflammation both in the sampled lesions, as shown by the increase in Ikb-α and the reduction in cytosolic expressions of COX2 as well as the reduction in nuclear localization of NFkB, and in peritoneal fluids, as shown by reduced levels of TNF-α, PGE2, and IL-1α. C8D has significant analgesic effects, as shown by reducing mast cell recruitment to the spinal cord and reducing the release of neurosensitizing and pro-inflammatory mediators.

In conclusion, the collected data showed that CBD has effective and coordinated effects in suppressing endometriosis.

Source: PubMed, “National Library of Medicine”

https://pubmed.ncbi.nlm.nih.gov/35628240/

Translation of the scientific study: " Medical cannabls for gynecological pain: A systematic review ", Liang AL, Gingher EL, Coleman JS.

Obstet Gynecol. 2022 Feb 1;139(2):287-296. doi: 10.1097/AOG.0000000000004656.

PMID: 35104069

Objective: The endocannabinoid system is involved in pain perception and inflammation. Cannabls contains delta-9-tetrahydrocannabinol (THC) and cannabidlol (C8D), cannablnoids that bind to receptors in the endocannablnoid system. A fatty acid amide called palmitoylethanolamide (PEA) strengthens endogenous cannablnoids. As its use is increasing, we sought to characterize patterns of use for gynecologic pain and its effectiveness as an analgesic.

Study Conclusion: Survey data showed that most women reported that cannabls improved pain due to many gynecological conditions. Cohort studies and a randomized controlled trial using medications combined with PEA have reported pain reduction. However, interpretation of studies is limited due to diversity in formulations, delivery methods, and dosages, preventing a definitive statement for gynecologic pain relief.

Source: PubMed, “National Library of Medicine”

https://pubmed.ncbi.nlm.nih.gov/35104069/

Research question: “ Can cannabldiol (C8D) be used in the treatment of endometriosis for its anti-inflammatory, antioxidant and antiangiogenic effects?” (against the proliferation of endometriotic cells)

Okten SB, Cetin C, Tok OE, Guler EM, Taha SH, Ozcan P, Ficicioglu C.

Reprod Biomed Online. 2023 May;46(5):865-875. doi: 10.1016/j.rbmo.2023.01.018. Epub 2023 Feb 2.

PMID: 36997400

Results: Significant reductions in endometriotic implant surface area (P = 0.0213), serum concentrations of TOS (P = 0.0491), OSI (P = 0.0056), IL-6 (P = 0.0236), TNF-α (P = 0.0083) and OSI (P = 0.0401), IL-6 (P = 0.0205) and TNF-α (P = 0 .0045) in peritoneal fluid were observed in the CBD5 group compared to the saline group. Compared with the saline group, increased TAS concentrations in serum (P = 0.0012) and peritoneal fluid (P = 0.0145) were observed in the CBD5 group. The CBD5 and leuprolide acetate groups were similar with respect to inflammatory and oxidative stress parameters of serum and peritoneal fluid samples. The CBD5 group showed significantly lower mean intensity in surface epithelium and stromal cells for VEGF (both P = 0.002) and only in surface epithelium cells for IL-6 (P = 0.0108), compared to the leuprolide acetate group.

Conclusion: Due to its anti-inflammatory, antioxidant and antiangiogenic effects, C8D could be a candidate therapeutic agent for endometriosis.

Source: PubMed, “National Library of Medicine”,

https://pubmed.ncbi.nlm.nih.gov/36997400/

Il n'y a pas eu d'alerte Cosmed à ce sujet car ces substances ne sont pas autorisées en cosmétique (essentiellement concernés : les produits à ingérer et à vapoter pour lesquels il y a eu des effets indésirables graves). Pour rappel, seul le CBD et l'huile de chanvre sont utilisées (autorisées en cosmétique).

Les substances qui vont être interdites par l'ANSM sont:

- leH2-cannabidiol (H2CBD)et le H4-cannabidiol (H4CBD)qui sont les formes hydrogénées du cannabidiol et donc des. cannabinoïdes hémi-synthétiques. Le cannabidiol hydrogéné est un cannabidiol qui a été soumis à une hydrogénation, un processus de saturation des doubles liaisons dans les molécules en utilisant une source d'hydrogène en présence d'un catalyseur tel que le palladium ou l'oxyde de platine.Le cannabidiol (CBD) que nous utilisons n'est donc pas concerné. Le CBD utilisé chez GBC est obtenu par extraction supercritique au CO2 de la plante, seul traitement subi. Il s'agit donc de CBD et non de H2CBD ou H4CBD.

- les substances dérivées du noyau benzo[c]chromènequi possèdent donc un cycle aromatique qui intègre un noyau d'oxygène, comme dans le THC (cf. molécule ci-dessus).

- une liste également de 8 substances purementchimiques(5F-Cumyl-Pegaclone (ou 5F-SGT-151), Cumyl-CH-Megaclone (ou SGT-270), 7APAICA, 5F-7APAICA, Cumyl-P7AICA, 5F-Cumyl-P7AICA, BZO-Hexoxizid (ou MDA-19) et BZO-Poxizid (ou 5C-MDA-19)